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ORIGINAL ARTICLE

Relative Predictive Value of Circulating
Immune Markers in US Adults Without
Cardiovascular Disease: Implications for Risk
Reclassiﬁcation
Kartik Gupta, MD; Rajat Kalra, MBChB; Mike Pate, BS; Shivaraj Nagalli, MD;
Sameer Ather, MD, PhD; Indranee Rajapreyar, MD; Pankaj Arora, MD;
Ankur Gupta, MD, PhD, SM; Wunan Zhou, MD, MPH;
Raul San Jose Estepar, MSc, PhD; Marcelo Di Carli, MD; Sumanth D. Prabhu, MD;
and Navkaranbir S. Bajaj, MD, MPH
Abstract
Objective: To investigate the relative predictive value of circulating immune cell markers for cardiovascular mortality in ambulatory adults without cardiovascular disease.
Methods: We analyzed data of participants enrolled in the National Health and Nutrition Examination
Survey from January 1, 1999, to December 31, 2010, with the total leukocyte count within a normal
range (4000-11,000 cells/mL [to convert to cells 109/L, multiply by 0.001]) and without cardiovascular disease. The relative predictive value of circulating immune cell markers measured at
enrollmentdincluding total leukocyte count, absolute neutrophil count, absolute lymphocyte count,
absolute monocyte count, monocyte-lymphocyte ratio (MLR), neutrophil-lymphocyte ratio, and Creactive proteindfor cardiovascular mortality was evaluated. The marker with the best predictive
value was added to the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score to estimate
net risk reclassiﬁcation indices for 10-year cardiovascular mortality.
Results: Among 21,599 participants eligible for this analysis, the median age was 47 years (interquartile range, 34-63 years); 10,651 (49.2%) participants were women, and 10,713 (49.5%) were selfreported non-Hispanic white. During a median follow-up of 9.6 years (interquartile range, 6.8-13.1
years), there were 627 cardiovascular deaths. MLR had the best predictive value for cardiovascular
mortality. The addition of elevated MLR (0.3) to the 10-year ASCVD risk score improved the
classiﬁcation by 2.7%1.4% (P¼.04). Elevated MLR had better predictive value than C-reactive
protein and several components of the 10-year ASCVD risk score.
Conclusion: Among ambulatory US adults without preexisting cardiovascular disease, we found that
MLR had the best predictive value for cardiovascular mortality among circulating immune markers.
The addition of MLR to the 10-year risk score signiﬁcantly improved the risk classiﬁcation of
participants.
ª 2020 Mayo Foundation for Medical Education and Research

A

ctivation of the immune system has
been described in cardiovascular
diseases, such as atherosclerosis,
acute coronary syndrome, and heart failure.1-4 The associated immune markers
may have prognostic signiﬁcance to detect
long-term cardiovascular events. However,

n
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the widely used cardiovascular risk prediction models do not include any immune
markers.5,6
Circulating
immune-inﬂammatory
markers such as C-reactive protein (CRP),
total leukocyte count, and differential leukocyte count are widely available, and studies
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report their independent association with
adverse cardiovascular outcomes.1-3,7,8 However, their ability to predict the long-term
risk of cardiovascular mortality in a population without cardiovascular disease remains
unknown. Furthermore, no previous study
has compared the relative predictive values
of these circulating immune markers.
Finally, it remains unclear how the predictive value of circulating immune markers
compares with that of traditional cardiovascular risk factors such as age, hypertension,
and dyslipidemia.
We investigated the role of widely available circulating immune cell markers to predict cardiovascular mortality in a
representative ambulatory US adult population without cardiovascular disease. We hypothesized that circulating immune cell
markers in the normal range are differentially associated with cardiovascular risk.
We aimed to rank their relative predictive
value and to explore how the addition of
these circulating immune cell markers to
current prediction models modiﬁes cardiovascular risk classiﬁcation.
METHODS
The study was conducted following the
Strengthening the Reporting of Observational Studies in Epidemiology guidelines
(Supplemental Table 1, available online at
http://www.mayoclinicproceedings.org).
Study Design and Participants
The National Health and Nutrition Examination Survey (NHANES) is a serial crosssectional survey designed to gather data
about the health status of the resident civilian
noninstitutionalized US population. The details of the interview, laboratory evaluation,
and physical examination have been published previously9 and are given in the
Supplemental Methods (available online at
http://www.mayoclinicproceedings.org). The
data are linked to the National Death Index
through December 31, 2011. We used publicly available deidentiﬁed data. Therefore,
approval from the University of Alabama at
Birmingham Institutional Review Board
was not required. Data from participants
2
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aged 18 years and older from 6 NHANES cycles from 1999 to 2010 were used for the
analysis (Figure 1).
We excluded participants with preexisting cardiovascular disease (self-reported
angina, heart attack, coronary artery disease,
heart failure, stroke, or pacemaker) or total
leukocyte count beyond the normal range
(<4000 cells/mL or >11,000 cells/mL [to
convert to cells 109/L, multiply by
0.001]). Other exclusion criteria are given
in the Supplemental Methods.
Study Variables
Several circulating immune markers, such as
total and differential leukocyte count and
CRP, used in this investigation were available from the blood sample collected at the
time of the visit to the mobile examination
center during NHANES. Details are given
in the Supplemental Methods and
Supplemental Table 2 (available online at
http://www.mayoclinicproceedings.org). We
computed the neutrophil-lymphocyte ratio
by dividing the absolute neutrophil count
by the absolute lymphocyte count and the
monocyte-lymphocyte ratio (MLR) by
dividing the absolute monocyte count by
the absolute lymphocyte count. Both these
ratios are independently associated with
worse cardiovascular prognosis.10,11
Demographic and Clinical Information
Data on other demographic and clinical
characteristics were collected during either
the interview or the visit to the mobile examination center. The variable codes and diagnostic criteria to deﬁne comorbidities are
given in the Supplemental Methods and
Supplemental Table 2.
Study Outcome
Cardiovascular mortality during follow-up
was the outcome for all survival analyses.
Cardiovascular mortality that occurred
within 10 years of the visit to the mobile examination center was the outcome for all logistic models. The cause of death was
derived from linked death certiﬁcate records
from the National Death Index.12 Details are
given in the Supplemental Methods and
XXX 2020;nn(n):1-10
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Supplemental Table 2. Follow-up time was
taken as time from mobile examination center date to the date of death or end of mortality period.
Statistical Analyses
Continuous variables were reported as medians with interquartile ranges (IQRs), and
categorical variables were represented as
counts with proportions. The Wilcoxon
rank sum test and c2 test were used to identify the differences in baseline characteristics
in continuous and categorical variables,
respectively. We estimated the 10-year
atherosclerotic
cardiovascular
disease
(ASCVD) and Framingham risk scores for
all participants.5,6 For calculation, participants younger than 40 years or older than
79 years were considered to be 40 years old
and 79 years old, respectively. The baseline
characteristics of the participants with age
younger than 40 years, 40 to 79 years, and
older than 79 years are given in
Supplemental Table 3 (available online at
http://www.mayoclinicproceedings.org).
The 10-year ASCVD and Framingham risk
scores varied across the NHANES cycle
(Supplemental Table 4, available online at
http://www.mayoclinicproceedings.org).
We assessed the relative predictive value
of circulating immune markers using the
Cox proportional hazards model and the logistic regression model. Details are given in
the Supplemental Methods. The optimal cutoff of the circulating immune marker with
the best predictive value for 10-year cardiovascular mortality was estimated using the Youden and Liu index.13,14 We then evaluated
the independent association of the marker
with the best predictive value at a categorical
cutoff ascertained in the previous step. We
used both the Cox proportional hazards
model and competing risk regression analysis
with noncardiovascular mortality as a
competing risk for cardiovascular mortality
in the adjusted model. The adjusted Cox proportional hazards model included the
following covariates: age, sex, race, hypertension, hemoglobin, diabetes mellitus, chronic
obstructive pulmonary disease, current

Total participants
(NHANES 1999-2010)
n=62,160
Excluded n=36,635
• Age <18 years n=26,781
• Missing leukocyte count/CRP n=26,152
• TLC outside normal range/ hematological
malignancy n=15,706
• Missing data to compute risk score n=3,876
• Pre-existing cardiovascular disease n=2,379
• Pregnant n=1,502
• HIV infection/on immunomodulation n=1,390
Total eligible participants
n=25,525

Follow-up available
n=21,599

FIGURE 1. Flow diagram for study selection. Normal range of total
leukocyte count (TLC) is deﬁned as 4000 to 11,000 cells/mL (to convert to
cells 109/L, multiply by 0.001). Cardiovascular disease is deﬁned as selfreported coronary artery disease, heart failure, stroke, or on pacemaker.
CRP, C-reactive protein; HIV, human immunodeﬁciency virus; NHANES,
National Health and Nutrition Examination Survey.

smoking, dyslipidemia, estimated glomerular
ﬁltration rate, malignant disease, obesity, and
NHANES cycle. The variables in multivariate
models were included if they were established
risk factors for cardiovascular events or associated with inﬂammation and cardiovascular
mortality. We also included the NHANES cycle as a covariate as sampling strategy changed
in NHANES over the years, which likely led to
variation in 10-year ASCVD risk across the
NHANES cycles. The proportionality assumption was veriﬁed using the Schoenfeld residuals.15 We determined whether there was a
dose-response relationship of cardiovascular
mortality with the marker with the best predictive value. Poisson regression analyses
were used to estimate the incident rate (per
100 person-years) of cardiovascular mortality.
Missing data for obesity (n¼291 [1.4%]) and
estimated glomerular ﬁltration rate (n¼54
[0.3%]) were imputed using multivariate
chained equations with age, sex, and race as
predictors.16 There was no difference in the
central tendency, spread, and predictive ability
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in the Cox model between the imputed and
the unimputed variables (Supplemental
Table 5, available online at http://www.
mayoclinicproceedings.org).
We also determined the independent
prognostic importance of all circulating immune markers using the Cox proportional
hazards model to predict cardiovascular
mortality.
Reclassiﬁcation and Comparison With CRP
and Components of ASCVD and Framingham Risk Scores
We then estimated the net reclassiﬁcation index (NRI) after adding the circulating immune marker with the best predictive value
in the same model as the 10-year ASCVD
risk score and the Framingham risk score
with a prespeciﬁed cutoff of 5% (low
risk).17 NRI helps compare the discriminative ability of 2 risk prediction models by logistic regression.17 The reclassiﬁcation
indices for both scores were also estimated
after the addition of CRP, given that it is
the most commonly used inﬂammatory
marker to predict cardiovascular outcomes.18 Furthermore, we ranked the predictive value of the components in the 10year ASCVD risk score, the Framingham
risk score, and the circulating immune
marker for 10-year cardiovascular mortality.
These factors were ranked by the likelihood
and Wald c2 statistics for the Cox proportional hazards analyses and by the area under the curve and standardized domination
statistic for the logistic regression analyses.11,12 All statistical analyses were performed
in
Stata/SE
version
15.1
(StataCorp). All P values were 2 sided, with
P value less than .05 considered statistically
signiﬁcant.
RESULTS
Baseline Characteristics
Among 62,160 participants in 6 NHANES
cycles spanning 1999 to 2010, there were
21,599 participants (34.7%) included in the
analyses (Figure 1). The baseline characteristics of the study population are given in
the Table.
4
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The median age of the participants was
47 years (IQR, 34-63 years), with 10,651
(49.2%) women and 10,713 (49.5%) selfidentiﬁed as non-Hispanic white. The prevalence of diabetes mellitus, hypertension, and
dyslipidemia was 13.8%, 52.8%, and 65.0%,
respectively (Table). The median leukocyte
count was 6900 cells/mL (IQR, 5700-8100
cells/mL). The median absolute neutrophil
and monocyte counts were 4000 cells/mL
(IQR, 3100-4900 cells/mL) and 500 cells/mL
(IQR, 400-600 cells/mL), respectively. The
median 10-year ASCVD risk score and Framingham risk score was 5% (IQR, 1.6%16.7%) and 7.4% (IQR, 2.0%-21.9%),
respectively.
The participants in the assembled cohort
were observed for a median of 9.6 years
(IQR, 6.8-13.1 years). Cause of death was
available in 99.8% of participants. There
were 627 deaths due to cardiovascular
causes at an incident rate of 0.29 per 100
person-years (95% CI, 0.27-0.32). Of these,
509 (81.2%) cardiovascular deaths were
within 10 years of follow-up.
Relative Predictive Value of Circulating Immune Markers
The MLR had the best predictive value for
10-year cardiovascular mortality (Figure 2)
in both time to event (using likelihood and
Wald c2 statistics) and logistic regression
analyses (area under the curve and standardized domination statistic). The risk of cardiovascular mortality was higher with 1 SD
rise of MLR (b¼.34) compared with 1 SD
rise of CRP (b¼.08; Wald c2 for comparison
of b in survival model ¼ 71.30; P<.001).
The optimal cutoff of the MLR to classify patients with the highest accuracy for the risk
of 10-year cardiovascular mortality using
the Youden index was 0.30 (Supplemental
Figure 1, available online at http://www.
mayoclinicproceedings.org). This cutoff had
a sensitivity and speciﬁcity of 55% and
69%. Participants with an elevated MLR
(0.3) had a higher risk of cardiovascular
mortality in the adjusted analysis (hazard ratio, 1.36; 95% CI, 1.15-1.60; P<.001;
Figure 3A) and the competing risk analysis
with noncardiovascular mortality as a
XXX 2020;nn(n):1-10
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competing risk (hazard ratio, 1.29; 95% CI,
1.09-1.52; P¼.003; Figure 3B) (all P<.05).
The effect estimates remained robust in the
adjusted model with unimputed data (hazard ratio, 1.37; 95% CI, 1.15-1.63; P<.001).
There was a dose-response relationship
such that the incidence of cardiovascular
mortality increased by 13% (95% CI, 6-21)
for every 1 unit increase in the MLR in the
adjusted model (Figure 4).
All immune markers except absolute
lymphocyte count were independently associated with cardiovascular mortality
(Supplemental Table 6, available online at
http://www.mayoclinicproceedings.org).
Reclassiﬁcation and Comparison With CRP
and Components of ASCVD and Framingham Risk Scores
Baseline demographic, clinical, and laboratory characteristics of participants by low
(<0.3) or elevated (0.3) MLR are given
in Supplemental Table 7 (available online
at http://www.mayoclinicproceedings.org).
The participants with elevated MLR were
older and included a higher representation
of men and non-Hispanic whites and individuals with hypertension, smoking, and
malignant disease. Participants in the
elevated MLR group had a signiﬁcantly
higher 10-year ASCVD score (8.3% vs
4.2%; P<.001) and Framingham risk score
(12.1% vs 6.0%; P<.001).
Addition of elevated MLR to the categorical 10-year ASCVD risk score
correctly up-classiﬁed 3.2% of participants
with cardiovascular mortality (49.3% to
52.2%) and incorrectly up-classiﬁed 0.4%
of participants with no cardiovascular
mortality (8.8% to 9.2%). There was a
signiﬁcant improvement in risk classiﬁcation (NRI, 2.71.4; P¼.04; Supplemental
Figure 2A, available online at http://
www.mayoclinicproceedings.org). Adding
elevated CRP to the categorical 10-year
ASCVD risk score had no impact on the
risk
classiﬁcation
(NRI,
0.20.0;
P¼.83; Supplemental Figure 2B). Risk
reclassiﬁcation with addition of other
circulating immune markers to the 10year ASCVD risk score with different

TABLE. Baseline Demographic, Clinical, and Laboratory Parameters in the
Assembled NHANES Cohort (1999-2010)a,b,c
Factor
Demographic parameters
Age (y)
Women
Race
Non-Hispanic white
Non-Hispanic black
Mexican American
Other Hispanic
Other race, including multiracial

Overall (N¼21,599)
47.0 (34.0-63.0)
10,651 (49.2)
10,713
3887
4660
1544
845

(49.5)
(18.0)
(21.5)
(7.1)
(3.9)

Anthropometry
Weight (kg)
Height (m)
Body mass index (kg/m2)

77.8 (66.4-91.0)
1.7 (1.6-1.8)
27.6 (24.2-31.6)

Comorbidities
Diabetes mellitus
Dyslipidemia
Hypertension
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Smoking
Chronic obstructive pulmonary disease
Malignant disease
Obesity

2977
14,082
11,441
122.0
72.0
10,143
122
750
7104

(13.8)
(65.0)
(52.8)
(112.0-135.0)
(64.0-79.0)
(46.9)
(0.6)
(5.7)
(33.3)

Laboratory parameters
Hemoglobin (g/dL)
Platelet count (cells 106/mL)
Estimated GFR (mL/min/1.73 m2)d

14.4 (13.4-15.4)
260.0 (223.0-305.0)
99.7 (82.1-122.0)

Circulating immune markers
C-reactive protein (mg/dL)
Total leukocyte count (cells 103/mL)
Absolute lymphocyte count (cells 103/mL)
Absolute neutrophil count (cells 103/mL)
Absolute monocyte count (cells 103/mL)
Absolute eosinophil count (cells 103/mL)
Absolute basophil count
(cells 103/mL)
Neutrophil-lymphocyte ratio
Monocyte-lymphocyte ratio

0.2
6.9
2.0
4.0
0.5
0.2
0.0

(0.1-0.4)
(5.7-8.1)
(1.7-2.5)
(3.1-4.9)
(0.4-0.6)
(0.1-0.2)
(0.0-0.1)

2.0 (1.5-2.6)
0.3 (0.2-0.3)

Risk score
10-year ASCVD riske (%)
10-year Framingham risk (%)

5.0 (1.6-16.7)
7.4 (2.0-22.0)

ASCVD, atherosclerotic cardiovascular disease; GFR, glomerular ﬁltration rate; NHANES, National Health and Nutrition Examination Survey.
b
To convert hemoglobin values to g/L, multiply by 10; to convert platelet count to cells 109/L,
multiply by 0.001; to convert C-reactive protein values to nmol/L, multiply by 95.24; to convert
white blood cell counts to cells 109/L, multiply by 0.001.
c
Data are represented as median (25th-75th percentile) or number (%).
d
GFR estimated by the Modiﬁcation of Diet in Renal Disease 4-component study equation.
e
For calculation of 10-year ASCVD risk, participants aged <40 years (n¼7,547 [34.9%]) or >79
years (n¼1,315 [6%]) were considered to be 40 and 79 years old, respectively. Neutrophillymphocyte and monocyte-lymphocyte ratio derived by dividing absolute neutrophil count and
absolute monocyte count by absolute lymphocyte count, respectively.
a
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statistical models is given in Supplemental
Table 8 (available online at http://www.
mayoclinicproceedings.org).
Similarly, adding elevated MLR to the 10year Framingham risk score signiﬁcantly
improved the reclassiﬁcation by correctly upclassifying 4% of participants with cardiovascular mortality (NRI, 4.01.2; P¼.001). Adding elevated CRP had no impact on the risk
classiﬁcation (NRI, 0.30.7; P¼.67).
Comparing the Relative Predictive Value of
MLR With Components of ASCVD and Framingham Risk Scores
We ranked the predictive value of the 9 components of the 10-year ASCVD risk score and
elevated MLR for cardiovascular mortality.
Age had the highest predictive value in all
models. The MLR ranked ﬁfth and had a
higher predictive value than race, smoking status, high-density lipoprotein level, and total
cholesterol concentration in both the time to
event and logistic regression models
(Supplemental Figure 3, available online at
http://www.mayoclinicproceedings.org). Similarly, it ranked ﬁfth compared with the components of the Framingham risk score.
DISCUSSION
We found that multiple circulating immune
markers were independently associated with
cardiovascular mortality during a median
follow-up of 9.6 years among ambulatory US
adults without preexisting cardiovascular disease and a total leukocyte count within the
normal range. Among the available circulating
immune markers, the MLR had the best predictive value. The MLR signiﬁcantly improved
the classiﬁcation power of the 10-year ASCVD
risk score and the Framingham risk score to
predict cardiovascular mortality and performed better than CRP as a predictor. In
addition, it had greater prognostic importance
than traditional cardiovascular risk factors
such as race, smoking status, high-density lipoprotein level, and total cholesterol
concentration.
Immune cells and inﬂammatory markers
have an important pathophysiologic role in
cardiovascular diseases. They are inﬂuenced
by myocardial stressors such as ischemia,
6
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volume overload, or pressure overload and
by comorbidities commonly associated with
cardiovascular diseases, such as dyslipidemia
and obesity.19,20 At a cellular level, there is
an increasing appreciation of the interplay
between cardiac myocytes and immune cells
during physiologic and pathologic states.
Extant literature suggests that there is an
initial inﬁltration of blood neutrophils and
then proinﬂammatory monocytes and
monocyte-derived macrophages to clear
necrotic debris after myocardial injury.21,22
Thereafter, tissue macrophages transition to
a phenotype of inﬂammation resolution
and tissue repair. This complex inﬂammatory response, initially directed at myocardial repair, may become dysregulated and
cause adverse cardiac remodeling and
worsen prognosis.23 These observations
lend biologic credence to our ﬁndings
whereby both neutrophils and monocytes
were independent risk factors for increased
cardiovascular mortality.
The critical role of monocytes in the
pathophysiologic process of cardiovascular
diseases such as atherosclerosis, heart failure, and atrial ﬁbrillation is well
described.24,25 Distinct subsets of circulating
monocytes with a proinﬂammatory or reparative phenotype have been identiﬁed in
humans and mouse models.21,26 The
elevated risk of cardiovascular death with
elevated neutrophil and monocyte counts
in our study may reﬂect ongoing myocardial
and vascular damage or dysregulated inﬂammation in ambulatory adults without preexisting cardiovascular disease.
We also found that a low lymphocyte
count is not an independent risk factor for
cardiovascular mortality, in contrast to previous reports in advanced heart failure.27
The association of a lower lymphocyte count
with cardiovascular mortality was not
observed in the fully adjusted model, suggesting that the adverse prognostic role of
decreased lymphocytes is likely to be mediated (or modulated) by other covariates.
Increased cortisol production during stress
shifts the leukocyte production in favor of
neutrophils and monocytes over lymphocytes.28 This might explain why the
XXX 2020;nn(n):1-10

n

https://doi.org/10.1016/j.mayocp.2020.11.027
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on May 10, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

IMMUNE MARKERS AND CARDIOVASCULAR DISEASE

280

155

254

240
200

106

Wald x2

Likelihood ratio x2

150

100

48 48

50

177

160
120
70

80
21 21

45 38

40

22

5

0

1

2

A

3 4 5
Ranking

6

5

7

1

C

3 4 5
Ranking

6

7

1.00

0.65 0.63

0.60

0.61 0.58

0.57 0.56

0.53

0.40
0.20

1

2

3 4 5
Ranking

6

Standardized domination statistic

0.80

0.00

2

B

1.00
Area under the curve (AUC)

neutrophil-lymphocyte ratio and MLR may
be a better marker of inﬂammation than absolute neutrophil or monocyte count.
Elevated CRP is a widely used marker for
adverse cardiovascular outcomes, both in the
general population and in patients with cardiovascular disease. Furthermore, CRP is the
most widely used inﬂammatory marker in
cardiovascular risk prediction models.7,8
The exact role of CRP in the pathogenesis
of cardiovascular diseases is not clear. In
atherosclerosis, it has been proposed that
some isoforms of CRP drive increased
expression of proinﬂammatory adhesion
molecules that mediate the migration of
monocytes to atheromatous plaques.29
Furthermore, activated monocytes in the
arterial wall have been reported to be critical
for hypertension-induced vascular remodeling in humans.30 These observations
together with a weaker association between
CRP and cardiovascular mortality in our
study led us to speculate that CRP may not
reliably indicate tissue-level immune cell
recruitment and dysregulated responses
compared with circulating immune cells.
Another possibility is that CRP may not be
as reliable as MLR as a marker of nonatherosclerotic (such as heart failure and cardiometabolic
disease)
myocardial
insult.
Furthermore, the monocytes recruited to
the myocardium may be the ﬁnal pathway
after myocardial damage leading to adverse
myocardial remodeling. Thus, monocytes
have a higher predictive value than lipoproteins that drive atherosclerosis and may associate with the severity of atherosclerosis at
the time of measurement in those without
established cardiovascular disease.31,32 Our
study ﬁnds that MLR may be a better risk
prognosticator than CRP in those without
prevalent CVD while validating the association of CRP with cardiovascular events.
Collectively,
these
conceivable
but
hypothesis-generating observations may
explain the higher predictive value of the
MLR than of CRP and lipoproteins to predict
cardiovascular mortality in our study.
The adverse prognostic implications of
readily available circulating immune cell
markers for adverse cardiovascular outcomes

0.80
0.60
0.40

0.24

0.20

0.16
0.09 0.07

0.00

7

0.32

1

D

Circulating immune marker
Monocyte-lymphocyte ratio
Absolute lymphocyte count
Absolute neutrophil count
Total leukocyte count

2

3 4 5
Ranking

0.06 0.05

6

7

Neutrophil-lymphocyte ratio
Absolute monocyte count
C-reactive protein

FIGURE 2. The relative predictive value of circulating immune markers to
predict CV mortality. The circulating immune markers are arranged in
decreasing order of importance. Likelihood ratio c2 using Cox Model to
predict CV mortality (panel A). Wald c2 using Cox Model to predict CV
mortality (panel B). The AUC using a logistic model to predict 10-year CV
mortality (panel C). Standardized domination statistic using a logistic model
to predict the relative importance of immune markers for 10-year CV
mortality (panel D).

in healthy participants have been previously
reported in separate studies.1,3,7,8,10,11 Despite
their independent adverse prognostic role,
traditional risk prediction models, such as
the 10-year ASCVD risk score, do not include
any immune markers.6 To the best of our
knowledge, this is the ﬁrst time that the relative contribution of total and differential
leukocyte counts, neutrophil-lymphocyte
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2.0
MLR ≥0.3
1.5
MLR <0.3
1.0

0.5
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Adjusted HR 1.36 (1.15, 1.60), P<.001
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FIGURE 3. Risk of cardiovascular mortality stratiﬁed by monocyte-lymphocyte ratio (MLR) in the Cox proportional hazards model (A)
and competing risk regression model with noncardiovascular mortality as competing risk (B) adjusted for age, sex, race, hypertension,
hemoglobin, diabetes mellitus, chronic obstructive pulmonary disease, current smoking, dyslipidemia, estimated glomerular ﬁltration
rate, malignant disease, obesity, and National Health and Nutrition Examination Survey cycle. HR, hazard ratio.
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pacemaker at baseline to exclude patients
with preexisting cardiovascular disease that
may have resulted in bias. However, previous data show good reliability and validity
of self-reported comorbidities in the
NHANES data.35 In the study population,
41% of participants were outside the age
range of ASCVD (<40 years or >79 years);
the 10-year ASCVD risk score estimation in
these participants may have overestimated

6
Incidence rate
(per 100 person-years)

ratio and MLR, and CRP have been compared
in a single risk prediction model with an
established risk score to predict 10-year cardiovascular mortality. Randomized controlled
trials have suggested a beneﬁcial role of
immunomodulation in secondary prevention
to reduce adverse cardiovascular events.33,34
Future studies in other prospective cohorts
are needed to validate these ﬁndings and to
investigate whether immunomodulation has
a role in the primary prevention of cardiovascular disease in individuals with a cardioinﬂammatory phenotype. Immune markers,
such as MLR, can help identify a subset of patients without cardiovascular disease who may
beneﬁt from immunomodulation.
Our study has important limitations. The
baseline values of circulating immune
markers were used in the prediction model.
We could not correlate temporal trends of
immune markers with cardiovascular mortality because of a lack of serial measurements in the NHANES. Even though we
excluded participants with leukocyte counts
outside the normal range, the measures of
circulating immune markers could have
been confounded by an acute illness at the
time of enrollment. We used a self-reported
history of heart attack, angina, coronary
heart disease, heart failure, stroke, and

Incidence rate ratio 1.13
(95% CI 1.06, 1.21), P<.001
4

2

0
.5
1
1.5
Monocyte-lymphocyte ratio

0

2

FIGURE 4. Dose-response relationship between monocyte-lymphocyte ratio and cardiovascular mortality. The solid green line
represents the incidence rate, and the dashed
green lines represent the 95% conﬁdence
interval (CI). There was a linear increase in the
risk of cardiovascular mortality with increase in
the monocyte-lymphocyte ratio.
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or underestimated the cardiovascular risk.
The 10-year ASCVD risk score predicts
future risk of nonfatal myocardial infarction
or coronary heart disease death or fatal or
nonfatal stroke during 10 years.6 However,
because of the lack of other outcomes in
the NHANES, we used cardiovascular mortality as an outcome, and it is plausible
that the 10-year ASCVD risk score overestimated the risk. However, the fact that the
up-classiﬁcation of risk of cardiovascular
mortality was better than the ASCVD score
indicates that it is unlikely that the results
observed in our study were simply due to
overestimation of risk.
CONCLUSION
Several circulating immune markers are
independently associated with cardiovascular mortality in ambulatory US adults. The
MLR has the best predictive value for cardiovascular mortality among readily available
circulating immune markers. Further study
is needed to conﬁrm our ﬁndings and to understand the pathobiologic mechanism linking immune cells and cardiovascular risk.
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